

Guillaume Fond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8736167/publications.pdf>

Version: 2024-02-01

214
papers

5,681
citations

109321
35
h-index

114465
63
g-index

253
all docs

253
docs citations

253
times ranked

7411
citing authors

#	ARTICLE	IF	CITATIONS
1	Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 651-660.	3.2	440
2	Beyond the association. <i>Toxoplasma gondii</i> in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 161-179.	4.5	346
3	Ketamine administration in depressive disorders: a systematic review and meta-analysis. <i>Psychopharmacology</i> , 2014, 231, 3663-3676.	3.1	278
4	The Prevalence of Mental Disorders Among Children and Adolescents in the Child Welfare System. <i>Medicine (United States)</i> , 2016, 95, e2622.	1.0	194
5	The "psychomicrobiotic": Targeting microbiota in major psychiatric disorders: A systematic review. <i>Pathologie Et Biologie</i> , 2015, 63, 35-42.	2.2	158
6	Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries. <i>JAMA Psychiatry</i> , 2021, 78, 1208.	11.0	155
7	Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 163-179.	4.5	140
8	EEG neurofeedback treatments in children with ADHD: an updated meta-analysis of randomized controlled trials. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 906.	2.0	115
9	Fasting in mood disorders: neurobiology and effectiveness. A review of the literature. <i>Psychiatry Research</i> , 2013, 209, 253-258.	3.3	108
10	Burnout in French physicians: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2019, 246, 132-147.	4.1	96
11	The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. <i>Schizophrenia Bulletin</i> , 2015, 41, 559-573.	4.3	93
12	The Role of Inflammation in the Treatment of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 160.	2.6	84
13	A National Network of Schizophrenia Expert Centres: an Innovative Tool to Bridge the Research-Practice Gap. <i>European Psychiatry</i> , 2015, 30, 728-735.	0.2	82
14	Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset. <i>Schizophrenia Bulletin</i> , 2016, 42, 1290-1302.	4.3	82
15	Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 624-634.	4.3	72
16	Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review. <i>Medical Hypotheses</i> , 2012, 79, 38-42.	1.5	70
17	A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. <i>Schizophrenia Research</i> , 2016, 171, 27-34.	2.0	61
18	Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort. <i>Schizophrenia Research</i> , 2015, 168, 388-394.	2.0	57

#	ARTICLE	IF	CITATIONS
19	End-of-life care among patients with schizophrenia and cancer: a population-based cohort study from the French national hospital database. <i>Lancet Public Health</i> , The, 2019, 4, e583-e591.	10.0	56
20	A further evaluation of decision-making under risk and under ambiguity in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 249-257.	3.2	53
21	C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 392.	2.6	53
22	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMISE cohort study. <i>Translational Psychiatry</i> , 2019, 9, 20.	4.8	52
23	Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries. <i>Molecular Psychiatry</i> , 2022, 27, 4172-4180.	7.9	52
24	(Mis)use of Prescribed Stimulants in the Medical Student Community. <i>Medicine (United States)</i> , 2016, 95, e3366.	1.0	50
25	Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort. <i>Schizophrenia Research</i> , 2017, 185, 173-181.	2.0	48
26	Driving us mad: the association of <i>Toxoplasma gondii</i> with suicide attempts and traffic accidents – a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2019, 49, 1608-1623.	4.5	47
27	Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 179-183.	3.2	46
28	Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 298-308.	4.3	45
29	Interleukin-1 β -targeted treatment strategies in inflammatory depression: toward personalized care. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 469-484.	4.5	44
30	Psychometric properties of the Ruminative Response Scale-short form in a clinical sample of patients with major depressive disorder. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 929-937.	1.8	42
31	Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. <i>Schizophrenia Research</i> , 2017, 182, 84-89.	2.0	41
32	Effectiveness of a housing support team intervention with a recovery-oriented approach on hospital and emergency department use by homeless people with severe mental illness: a randomised controlled trial. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e169.	3.9	40
33	D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. <i>Psychopharmacology</i> , 2014, 231, 3765-3770.	3.1	39
34	Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: A cross-sectional study. <i>Journal of Psychiatric Research</i> , 2015, 63, 58-64.	3.1	39
35	Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 985-992.	3.2	39
36	Victimization and posttraumatic stress disorder in homeless women with mental illness are associated with depression, suicide, and quality of life. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2269-2279.	2.2	38

#	ARTICLE	IF	CITATIONS
37	Early and very early-onset schizophrenia compared with adult-onset schizophrenia: French FACE-SZ database. <i>Brain and Behavior</i> , 2020, 10, e01495.	2.2	38
38	Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. <i>Journal of Affective Disorders</i> , 2016, 191, 209-215.	4.1	37
39	A preliminary study on cognitive enhancer consumption behaviors and motives of French Medicine and Pharmacology students. <i>European Review for Medical and Pharmacological Sciences</i> , 2014, 18, 1875-8.	0.7	37
40	Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review. <i>Psychiatry Research</i> , 2015, 229, 12-20.	3.3	36
41	Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. <i>British Journal of Psychiatry</i> , 2018, 213, 464-470.	2.8	35
42	Fasting Interventions for Stress, Anxiety and Depressive Symptoms: A Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2021, 13, 3947.	4.1	35
43	Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. <i>Schizophrenia Research</i> , 2015, 169, 255-261.	2.0	34
44	Google Trends®: Ready for real-time suicide prevention or just a Zeta-Jones effect? An exploratory study. <i>Psychiatry Research</i> , 2015, 228, 913-917.	3.3	34
45	Increased in-hospital mortality from COVID-19 in patients with schizophrenia. <i>L'Encephale</i> , 2021, 47, 89-95.	0.9	33
46	<p></p>Measuring the Patient Experience of Mental Health Care: A Systematic and Critical Review of Patient-Reported Experience Measures</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2147-2161.	1.8	32
47	Violent behavior and aggression in schizophrenia: Prevalence and risk factors. A multicentric study from three Latin-America countries. <i>Schizophrenia Research</i> , 2016, 178, 23-28.	2.0	31
48	Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 332-339.	4.8	31
49	Sexual dysfunctions in schizophrenia: Beyond antipsychotics. A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 98, 109804.	4.8	31
50	Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1130-e1136.	2.2	31
51	Mood disorders are associated with a more severe hypovitaminosis D than schizophrenia. <i>Psychiatry Research</i> , 2015, 229, 613-616.	3.3	30
52	A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression. <i>Scientific Reports</i> , 2016, 6, 19847.	3.3	29
53	Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 541-553.	3.2	29
54	High-intensity end-of-life care among children, adolescents, and young adults with cancer who die in the hospital: A population-based study from the French national hospital database. <i>Cancer</i> , 2019, 125, 2300-2308.	4.1	29

#	ARTICLE	IF	CITATIONS
55	Disparities in suicide mortality trends between United States of America and 25 European countries: retrospective analysis of WHO mortality database. Scientific Reports, 2016, 6, 20256.	3.3	27
56	Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort. Schizophrenia Research, 2018, 201, 373-380.	2.0	27
57	Machine learning for predicting psychotic relapse at 2â€ years in schizophrenia in the national FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 8-18.	4.8	27
58	Self-reported major depressive symptoms at baseline impact abstinence prognosis in smoking cessation program. A one-year prospective study. Journal of Affective Disorders, 2013, 149, 418-421.	4.1	26
59	Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. Schizophrenia Research, 2016, 175, 161-167.	2.0	26
60	Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset. European Neuropsychopharmacology, 2018, 28, 24-36.	0.7	26
61	<p>The Patient-Reported Experience Measure for Improving qUality of care in Mental health (PREMIUM) project in France: study protocol for the development and implementation strategy</p>. Patient Preference and Adherence, 2019, Volume 13, 165-177.	1.8	26
62	Cognitive insight as an indicator of competence to consent to treatment in schizophrenia. Schizophrenia Research, 2013, 144, 118-121.	2.0	25
63	Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. Schizophrenia Research, 2015, 165, 94-96.	2.0	24
64	Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 17-26.	3.2	23
65	Prevalence of and Risk Factors for Extrapyrimal Side Effects of Antipsychotics. Journal of Clinical Psychiatry, 2019, 80, .	2.2	23
66	A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia. Translational Psychiatry, 2015, 5, e608-e608.	4.8	22
67	Venus and Mars on the benches of the faculty: Influence of gender on mental health and behavior of medical students. Results from the BOURBON national study. Journal of Affective Disorders, 2018, 239, 146-151.	4.1	22
68	Psychiatric and psychological follow-up of undergraduate and postgraduate medical students: Prevalence and associated factors. Results from the national BOURBON study. Psychiatry Research, 2019, 272, 425-430.	3.3	22
69	Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 449-457.	3.2	22
70	Nanopsychiatryâ€The potential role of nanotechnologies in the future of psychiatry: A systematic review. European Neuropsychopharmacology, 2013, 23, 1067-1071.	0.7	21
71	Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset. Psychopharmacology, 2016, 233, 571-578.	3.1	21
72	Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 567-577.	3.2	21

#	ARTICLE	IF	CITATIONS
73	Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia. Journal of Clinical Psychiatry, 2018, 79, .	2.2	21
74	Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study. Schizophrenia Bulletin Open, 2021, 2, sgab012.	1.7	20
75	The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome). International Psychogeriatrics, 2011, 23, 505-507.	1.0	19
76	Validation of the Medication Adherence Rating Scale in homeless patients with schizophrenia: Results from the French Housing First experience. Scientific Reports, 2016, 6, 31598.	3.3	19
77	Psychiatry: A discipline at specific risk of mental health issues and addictive behavior? Results from the national BOURBON study. Journal of Affective Disorders, 2018, 238, 534-538.	4.1	19
78	Anxiolytic consumption is associated with tobacco smoking and severe nicotine dependence. Results from the national French medical students (BOURBON) study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109645.	4.8	19
79	Prevalence and Smoking Behavior Characteristics of Nonselected Smokers With Childhood and/or Adult Self-Reported ADHD Symptoms in a Smoking-Cessation Program. Journal of Attention Disorders, 2015, 19, 293-300.	2.6	18
80	Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 465-472.	3.2	18
81	WAIS-IV Seven-Subtest Short Form: Validity and Clinical Use in Schizophrenia. Archives of Clinical Neuropsychology, 2016, 31, 915-925.	0.5	17
82	Birth by cesarean section and schizophrenia: results from the multicenter FACE-SZ data-set. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 587-594.	3.2	17
83	Relationships between social stigma, stigma experience and self-stigma and impaired quality of life in schizophrenia across three Latin-American countries. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 513-520.	3.2	17
84	Pregnancy, delivery and neonatal complications in women with schizophrenia: a national population-based cohort study. Lancet Regional Health - Europe, The, 2021, 10, 100209.	5.6	17
85	Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). Cell Death and Disease, 2020, 11, 502.	6.3	16
86	Treating patients with schizophrenia deficit with erythropoietin?. Psychiatry and Clinical Neurosciences, 2012, 66, 375-382.	1.8	15
87	Risk factors for increased duration of untreated psychosis. Results from the FACE-SZ dataset. Schizophrenia Research, 2018, 195, 529-533.	2.0	15
88	Potentially inappropriate psychotropic prescription at discharge is associated with lower functioning in the elderly psychiatric inpatients. A cross-sectional study. Psychopharmacology, 2016, 233, 2549-2558.	3.1	14
89	Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. Journal of Psychiatric Research, 2017, 94, 62-69.	3.1	14
90	Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 62-68.	4.8	14

#	ARTICLE	IF	CITATIONS
91	Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.. Psychiatry Research, 2018, 270, 104-110.	3.3	14
92	Towards an improved access to psychiatric rehabilitation: availability and effectiveness at 1-year follow-up of psychoeducation, cognitive remediation therapy, cognitive behaviour therapy and social skills training in the FondaMental Advanced Centers of Expertise-Schizophrenia (FACE-SZ) national cohort. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 599-610.	3.2	14
93	Improving diet for psychiatric patients: High potential benefits and evidence for safety. Journal of Affective Disorders, 2020, 265, 567-569.	4.1	14
94	Physical Activity as a Protective Factor in Relapse Following Smoking Cessation in Participants with a Depressive Disorder. American Journal on Addictions, 2012, 21, 348-355.	1.4	13
95	Cyborg psychiatry to ensure agency and autonomy in mental disorders. A proposal for neuromodulation therapeutics. Frontiers in Human Neuroscience, 2013, 7, 463.	2.0	13
96	Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109654.	4.8	13
97	Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 84-89.	4.8	13
98	Use of artificial nutrition near the end of life: Results from a French national population-based study of hospitalized cancer patients. Cancer Medicine, 2020, 9, 530-540.	2.8	13
99	Anxiety and depression in young physicians: Prevalence and associated factors. The MESSIAEN national study. L'Encephale, 2022, 48, 26-30.	0.9	13
100	Septic shock: incidence, mortality and hospital readmission rates in French intensive care units from 2014 to 2018. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101082.	1.4	13
101	Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 879-886.	3.2	12
102	Illness and drug modifiable factors associated with violent behavior in homeless people with severe mental illness: results from the French Housing First (FHF) program. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 92-96.	4.8	12
103	Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 226-234.	4.8	12
104	The role of neighbourhood socioeconomic status in large for gestational age. PLoS ONE, 2020, 15, e0233416.	2.5	12
105	The covariation of independent and dependant variables in neurofeedback: A proposal framework to identify cognitive processes and brain activity variables. Consciousness and Cognition, 2014, 26, 162-168.	1.5	11
106	Gender differences in schizophrenia: A multicentric study from three Latin-America countries. Psychiatry Research, 2018, 266, 65-71.	3.3	11
107	Sexual-orientation based discrimination is associated with anxiety and depression in young physicians. A national study.. Journal of Affective Disorders, 2020, 274, 964-968.	4.1	11
108	Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109927.	4.8	11

#	ARTICLE	IF	CITATIONS
109	A conceptual framework to develop a patient-reported experience measure of the quality of mental health care: a qualitative study of the PREMIUM project in France. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 1885789.	1.5	11
110	Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort.. <i>Journal of Affective Disorders</i> , 2020, 274, 617-623.	4.1	11
111	Medication nonadherence among South American patients with schizophrenia. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1737-1744.	1.8	10
112	Relationship between childhood trauma and level of insight in schizophrenia: A path-analysis in the national FACE-SZ dataset. <i>Schizophrenia Research</i> , 2019, 208, 90-96.	2.0	10
113	Unplanned readmission and survival after video-assisted thoracic surgery and open thoracotomy in patients with non-small-cell lung cancer: a 12-month nationwide cohort study. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 987-995.	1.4	10
114	Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia. <i>Schizophrenia Research</i> , 2016, 178, 1-5.	2.0	9
115	Influence of Venus and Mars in the cognitive sky of schizophrenia. Results from the first-step national FACE-SZ cohort. <i>Schizophrenia Research</i> , 2018, 195, 357-365.	2.0	9
116	The need to improve detection and treatment of physical pain of homeless people with schizophrenia and bipolar disorders. Results from the French Housing First Study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 88, 175-180.	4.8	9
117	Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 1196.	2.4	9
118	Sexual harassment exposure and impaired mental health in medical students. The MESSIAEN national study. <i>Journal of Affective Disorders</i> , 2020, 274, 276-281.	4.1	9
119	Risk factors for burnout and depression in healthcare workers: The national AMADEUS study protocol. <i>L'Encephale</i> , 2022, 48, 247-253.	0.9	9
120	Would I take antipsychotics, if I had psychotic symptoms? Examining determinants of the decision to take antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 77, 155-163.	4.8	8
121	Abnormal C-reactive protein blood levels as a specific biomarker of major depression and non-remission under antidepressants in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 97, 109800.	4.8	8
122	Recurrent major depressive disorder's impact on end-of-life care of cancer: A nationwide study. <i>Journal of Affective Disorders</i> , 2020, 263, 326-335.	4.1	8
123	Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 271, 1571-1578.	3.2	8
124	<p>Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 1595-1604.	1.8	8
125	End of life breast cancer care in women with severe mental illnesses. <i>Scientific Reports</i> , 2021, 11, 10167.	3.3	8
126	Work environment and mental health in nurse assistants, nurses and health executives: Results from the AMADEUS study. <i>Journal of Nursing Management</i> , 2022, 30, 2268-2277.	3.4	8

#	ARTICLE	IF	CITATIONS
127	Schizophrenia pregnancies should be given greater health priority in the global health agenda: results from a large-scale meta-analysis of 43,611 deliveries of women with schizophrenia and 40,948,272 controls. <i>Molecular Psychiatry</i> , 2022, 27, 3294-3305.	7.9	8
128	Smoking behavior characteristics of non-selected smokers with childhood attention-deficit/hyperactivity disorder (AD/HD) history: a systematic review and meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 379-389.	3.2	7
129	Advanced Paternal Age is associated with earlier schizophrenia onset in offspring. Results from the national multicentric FACE-SZ cohort. <i>Psychiatry Research</i> , 2017, 254, 218-223.	3.3	7
130	Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2017, 52, 1113-1122.	3.1	7
131	A multi-dimensional approach to the relationship between insight and aggressiveness in schizophrenia: Findings from the FACE-SZ cohort. <i>Schizophrenia Research</i> , 2019, 204, 38-45.	2.0	7
132	The Latin American version of the internalized stigma of mental illness scale (LA-ISMI): a multicentric validation study from three Latin American countries. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 175.	2.4	7
133	Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort. <i>Journal of Affective Disorders</i> , 2019, 245, 468-474.	4.1	7
134	Trauma-related mortality of patients with severe psychiatric disorders: population-based study from the French national hospital database. <i>British Journal of Psychiatry</i> , 2020, 217, 568-574.	2.8	7
135	The puzzle of quality of life in schizophrenia: putting the pieces together with the FACE-SZ cohort. <i>Psychological Medicine</i> , 2022, 52, 1501-1508.	4.5	7
136	End-of-Life Care Among Patients With Bipolar Disorder and Cancer: A Nationwide Cohort Study. <i>Psychosomatic Medicine</i> , 2020, 82, 722-732.	2.0	7
137	Machine-learning prediction of unplanned 30-day rehospitalization using the French hospital medico-administrative database. <i>Medicine (United States)</i> , 2020, 99, e22361.	1.0	7
138	Repeated bullying at the workplace in medical students and young doctors: the MESSIAEN national study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1123-1131.	3.2	7
139	First-year French medical students consume antidepressants and anxiolytics while second-years consume non-medical drugs.. <i>Journal of Affective Disorders</i> , 2020, 265, 71-76.	4.1	7
140	Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission.. <i>Journal of Affective Disorders</i> , 2021, 280, 267-271.	4.1	7
141	Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 382-394.	4.3	7
142	Improving the treatment and remission of major depression in homeless people with severe mental illness: The multicentric French Housing First (FHF) program. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109877.	4.8	7
143	Brain SPECT perfusion and PET metabolism as discordant biomarkers in major depressive disorder. <i>EJNMMI Research</i> , 2020, 10, 121.	2.5	7
144	Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110479.	4.8	7

#	ARTICLE	IF	CITATIONS
145	ADHD prevalence in patients with hypersexuality and paraphilic disorders: a systematic review and meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 1413-1420.	3.2	7
146	Do the treasures of "big data"™ combined with behavioural intervention therapies contain the key to the mystery of large psychiatric issues?. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 406-407.	4.5	6
147	The World Health Organization (WHO) dataset for guiding suicide prevention policies: A 3-decade French national survey. <i>Journal of Affective Disorders</i> , 2015, 188, 232-238.	4.1	6
148	Pharmacoterrorism: the potential role of psychoactive drugs in the Paris and Tunisian attacks. <i>Psychopharmacology</i> , 2016, 233, 933-935.	3.1	6
149	Confirmation of a Two-Factor Solution to the Questionnaire of Cognitive and Affective Empathy in a French Population of Patients With Schizophrenia Spectrum Disorders. <i>Frontiers in Psychiatry</i> , 2019, 10, 751.	2.6	6
150	Brain PET metabolic substrate of TMS response in pharmaco-resistant depression. <i>Brain Stimulation</i> , 2020, 13, 683-685.	1.6	6
151	Peripheral inflammation is associated with brain SPECT perfusion changes in schizophrenia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 905-912.	6.4	6
152	C-reactive protein as a differential biomarker of bipolar II depression versus major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 71-72.	2.6	5
153	The Covid-19 infection: An opportunity to develop systematic vitamin D supplementation in psychiatry. <i>L'Encephale</i> , 2022, 48, 102-104.	0.9	5
154	Mortality among inpatients with bipolar disorders and COVID-19: a propensity score matching analysis in a national French cohort study. <i>Psychological Medicine</i> , 2023, 53, 1979-1988.	4.5	5
155	Comparison of three scales (BIS, SUMD and BCIS) for measuring insight dimensions and their evolution after one-year of follow-up: Findings from the FACE-SZ Cohort. <i>Psychiatry Research</i> , 2021, 303, 114044.	3.3	5
156	Handedness as a neurodevelopmental marker in schizophrenia: Results from the FACE-SZ cohort. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 525-536.	2.6	5
157	Ketamine™s effectiveness in unipolar versus bipolar depression. <i>Psychopharmacology</i> , 2014, 231, 4417-4418.	3.1	4
158	Inflammation in psychiatric disorders. <i>European Psychiatry</i> , 2014, 29, 551-552.	0.2	4
159	Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder. <i>Psychiatry Research</i> , 2014, 216, 286-287.	3.3	4
160	Abnormal C-reactive protein (CRP) levels in schizophrenia and schizoaffective disorders. Results from the FACE-SZ dataset. <i>European Psychiatry</i> , 2015, 30, S112-S112.	0.2	4
161	Psychiatric disability as mediator of the neurocognition-functioning link in schizophrenia spectrum disorders: SEM analysis using the Evaluation of Cognitive Processes involved in Disability in Schizophrenia (ECPDS) scale. <i>Schizophrenia Research</i> , 2018, 201, 196-203.	2.0	4
162	Outcome prediction with a social cognitive battery: a multicenter longitudinal study. <i>NPJ Schizophrenia</i> , 2021, 7, 30.	3.6	4

#	ARTICLE	IF	CITATIONS
163	Recently discovered properties of aspirin may be doubly helpful in bipolar disorders. Medical Hypotheses, 2014, 82, 640-641.	1.5	3
164	Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale. Clinical Rehabilitation, 2019, 33, 113-119.	2.2	3
165	Assessing metacognitive and help-seeking strategies in schizophrenia: design and psychometric validation of the Versailles Metacognitive Strategies Evaluation Questionnaire. Clinical Rehabilitation, 2020, 34, 263-275.	2.2	3
166	Hazardous drinking is associated with hypnotic consumption in medical students in the BOURBON nationwide study: psychological factors explored. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 883-889.	3.2	3
167	Prevalence and associated factors of cannabis consumption in medical students: the BOURBON nationwide study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 857-864.	3.2	3
168	Handedness in bipolar disorders is associated with specific neurodevelopmental features: results of the BD-FACE cohort. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 827-838.	3.2	3
169	Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110275.	4.8	3
170	Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110335.	4.8	3
171	The Validity of the SQoL-18 in Patients with Bipolar and Depressive Disorders: A Psychometric Study from the PREMIUM Project. Journal of Clinical Medicine, 2022, 11, 743.	2.4	3
172	Development and Calibration of the PREMIUM Item Bank for Measuring Respect and Dignity for Patients with Severe Mental Illness. Journal of Clinical Medicine, 2022, 11, 1644.	2.4	3
173	Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ dataset. European Psychiatry, 2015, 30, S130-S130.	0.2	2
174	Medication and aggressiveness in "real world" schizophrenia: current issues and perspectives. Psychopharmacology, 2016, 233, 2421-2423.	3.1	2
175	(Mis)use of prescribed stimulants in the medical student community: Motives and behaviors. A population-based cross-sectional study. European Neuropsychopharmacology, 2016, 26, S348-S349.	0.7	2
176	Mise en place et Évaluation de "ances d'Éthique appliquée dans un service de psychiatrie générale en France. Annales Medico-Psychologiques, 2020, 178, 884-890.	0.4	2
177	Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 703-714.	2.6	2
178	Early-life factors associated with increased risk of disability pension in the national real-world schizophrenia FACE-SZ cohort study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1379-1384.	3.2	2
179	Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort. Brain, Behavior, & Immunity - Health, 2022, 22, 100436.	2.5	2
180	Barriers and opportunities for the continuous training of healthcare professionals in the post-Covid era. L'Encephale, 2022, 48, 117.	0.9	2

#	ARTICLE	IF	CITATIONS
181	Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort. Cognitive Neuropsychiatry, 2022, 27, 49-68.	1.3	2
182	Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ). European Archives of Psychiatry and Clinical Neuroscience, 2022, 1.	3.2	2
183	Aspirin for prevention of cardiovascular events in bipolar disorders. Psychiatry Research, 2014, 219, 238-239.	3.3	1
184	Akathisia: Prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the multi-center FACE-SZ Dataset. European Psychiatry, 2016, 33, S96-S97.	0.2	1
185	The association between initial motivation for medical studies and specialty choice in young French physicians. L'Encephale, 2021, 47, 1-3.	0.9	1
186	Which antipsychotics should be chosen for the treatment of schizo-obsessive disorder?. L'Encephale, 2022, 48, 349-350.	0.9	1
187	You get psychotropic drugs, so you don't need vaccination against Covid 19?. L'Encephale, 2021, 47, 87-88.	0.9	1
188	Psychiatry Has to Take Care of Its Image On-Screen. primary care companion for CNS disorders, The, 2011, 13, .	0.6	1
189	Malformations and pregnancy with schizophrenia " Authors' reply. Lancet Regional Health - Europe, The, 2021, 11, 100257.	5.6	1
190	P.1.f.001 Drug repositioning of anti-inflammatory drugs in major psychiatric disorders. European Neuropsychopharmacology, 2013, 23, S185.	0.7	0
191	Troubles obsessionnels compulsifs r�sistants et antipsychotiques�: donn�es neurobiologiques et th�rapeutiques actuelles. Annales Medico-Psychologiques, 2013, 171, 725-732.	0.4	0
192	Utilisation des antid�presseurs de seconde g�n�ration (SGA) dans la pratique quotidienne du m�decin�: une synth�se � l'usage du clinicien. Annales Medico-Psychologiques, 2013, 171, 198-203.	0.4	0
193	Anti-inflammatory drugs add-on therapy in major psychiatric disorders. European Psychiatry, 2015, 30, S24-S25.	0.2	0
194	Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset. European Psychiatry, 2015, 30, S153-S154.	0.2	0
195	Ketamine vs other anesthetic agents for electroconvulsive therapy (ECT) in major depression. Journal of Psychiatric Research, 2015, 68, 226-227.	3.1	0
196	Dealing with current tobacco smoking in real world schizophrenia. Results from the Face-Schizophrenia dataset. European Neuropsychopharmacology, 2016, 26, S578-S579.	0.7	0
197	Cognitive impairment associated with benzodiazepine long-term administration in schizophrenia, results from the multicentre FACE-SZ dataset. European Neuropsychopharmacology, 2016, 26, S326.	0.7	0
198	Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia, results from the multicentric FACE-SZ dataset. European Neuropsychopharmacology, 2016, 26, S499.	0.7	0

#	ARTICLE	IF	CITATIONS
199	Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ dataset. European Psychiatry, 2016, 33, S98-S98.	0.2	0
200	Motives And Behaviors of Medical Students (mis)using Prescription Stimulants. European Psychiatry, 2016, 33, S448-S448.	0.2	0
201	Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset. European Psychiatry, 2016, 33, s242-s243.	0.2	0
202	Birth by cesarean section and schizophrenia. Results from the multi-center FACE-SZ dataset. European Psychiatry, 2016, 33, S98-S98.	0.2	0
203	Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia. Results from the Face-SZ dataset. European Psychiatry, 2017, 41, s831-s831.	0.2	0
204	Current Smoking in Real World Schizophrenia: Relationship to Psychopathology and Clinical Characteristics. Results from the FACE Dataset. European Psychiatry, 2017, 41, S98-S98.	0.2	0
205	Le microbiote intestinal gouverne-t-il notre cerveau? Annales Medico-Psychologiques, 2018, 176, 824-830.	0.4	0
206	Microbiote et dépression: une piste thérapeutique prometteuse. Annales Medico-Psychologiques, 2019, 177, 695-697.	0.4	0
207	Cross-Cultural Adaptation and Validation of the Quality of Life Questionnaire for Caregivers of Patients with Schizophrenia (S-CGQoL) in Latin America. L'Encephale, 2021, 47, 291-298.	0.9	0
208	Psychonutritional intervention for autism spectrum disorders. L'Encephale, 2021, 47, 289-290.	0.9	0
209	L'immunopsychiatrie existe-t-elle ?. Phytotherapie, 2018, 16, 347-352.	0.1	0
210	How to treat inflammatory schizophrenia?. L'Encephale, 2020, 46, 411-413.	0.9	0
211	Barriers in psychiatrists' mind to active smoking cessation promotion in severe psychiatric disorders. L'Encephale, 2023, 49, 21-26.	0.9	0
212	Psychotic symptomatology and medication adherence in patients with schizophrenia: The mediating effect of awareness of mental disorder. Schizophrenia Research, 2022, 241, 110-112.	2.0	0
213	ADHD and addictive behavior in crack-cocaine users. L'Encephale, 2022, , .	0.9	0
214	Intensive end-of-life care in acute leukemia from a French national hospital database study (2017-2018). BMC Palliative Care, 2022, 21, 45.	1.8	0